TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1449275
Drug: Retreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retreatment with the same dose of ivermectin after six months
Study: 30193556
Drug: 50% Concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% Concurrent and 100% Terminal (50% C & 100% T)
Study: 30193556
Drug: 0% Concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% Concurrent and 100% Terminal (0% C & 100% T)
Study: 30193556
Drug: 100% Concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% Concurrent and Terminal (100% C&T)
Study: 27392045
Drug: Gluten (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten (20 g/day)
Study: 24439191
Drug: Intravenous ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ceftazidime treatment
Study: 24439191
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prophylaxis of antibiotics)
Study: 7612386
Drug: Plasmapheresis (PP)
Normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmapheresis (PP) therapy only
Study: 7612386
Drug: Plasmapheresis (PP)
Normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmapheresis (PP) + high dose intravenous methylprednisolone therapy (pulse therapy)
Study: 7612386
Drug: Repeated Plasmapheresis
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated Plasmapheresis (PP) + pulse therapy
Study: 2198157
Drug: Pirazolac (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirazolac (300-600 mg b.i.d.)
Study: 2198157
Drug: Indomethacin (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25-50 mg t.i.d.)
Study: 31537689
Drug: Conventional or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional or intensified chemotherapy
Study: 26395866
Drug: MDMA (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (125 mg orally)
Study: 12975594
Drug: Orbiofan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbiofan (50 mg BID)
Study: 9172027
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of rocuronium 0.06 mg/kg followed two minutes later by an intubating dose of rocuronium 0.54 mg/kg
Study: 3549843
Drug: Indomethacin, 100
Normalized name: Indomethacin, 100 mg rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, 100 mg per day
Study: 28796588
Drug: G-CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CHOP
Study: 15730413
Drug: High-dose rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rhGH (0.2 U/kg/day)
Study: 15730413
Drug: Low-dose rhGH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rhGH (0.1 U/kg/day)
Study: 10389710
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg PGE2 gel
Study: 20027351
Drug: Ultralow doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultralow doses of antibodies to human IFN-gamma (anaferon pediatric formulation and anaferon)
Study: 9677555
Drug: Peribulbar injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peribulbar injection (9 ml of anaesthetic from an inferotemporal site)
Study: 9677555
Drug: Retrobulbar injection
Normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar injection (local anaesthetic through conjunctiva and facialis blockade)
Study: 8303829
Drug: Kicking to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kicking to move a block mobile displaying horizontal and vertical lines (textons) arranged as L, T, or +
Study: 2467588
Drug: Morphine 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1.8 mg iv every 8 min as required
Study: 2467588
Drug: Meperidine 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 18 mg iv every 8 min as required
Study: 2467588
Drug: Oxymorphone 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone 0.3 mg iv every 8 min as required
Study: 28224442
Drug: SAP+PERT (Strength,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAP+PERT (Strength, Agility, and Secondary Prevention treatment plus Perturbation Training)
Study: 8100911
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine given at induction of anaesthesia (iv pre)
Study: 8100911
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine given 1 hour before operation (im pre)
Study: 8100911
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine given at closure of the peritoneum (iv post)
Study: 3520204
Drug: Cianidanol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cianidanol (1.5 g daily for 2 weeks, then 2.25 g for 14 weeks)
Study: 27883319
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HRT and walking
Study: 17396068
Drug: Nisoldipine coat-core
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine coat-core (CC)
Study: 7604380
Drug: Total Parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Parenteral Nutrition (TPN) in patients with sepsis
Study: 7604380
Drug: Total Parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Parenteral Nutrition (TPN) in ambulatory patients receiving HPN
Study: 1970738
Drug: Bupivacaine-morphine mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine-morphine mixture (0.125% bupivacaine with morphine 0.05 mg kg‐1)
Study: 1970738
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Bupivacaine-morphine mixture and Bupivacaine alone)
Study: 396690
Drug: amoxycillin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxycillin 1.5 g daily
Study: 396690
Drug: ampicillin 4
Normalized name: ampicillin 45 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ampicillin 4 g daily
Study: 29799344
Drug: Ketamine (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (any dose)
Study: 31486447
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg resveratrol per day
Study: 19930904
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with Ulinastatin plus Thymosin‐alpha(1)
Study: 15917722
Drug: HESA‐A (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: HESA‐A (50 mg/kg/day)
Study: 12684572
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with antioxidant vitamins and minerals at nutritional doses
Study: 1817626
Drug: 0.375% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% bupivacaine 45 ml (168.75 mg) with adrenaline 1 in 200,000
Study: 1817626
Drug: Plain solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain solution (bupivacaine without adrenaline)
Study: 15257046
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of steroid-free versus steroids at 3 months
Study: 15257046
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of steroid-free versus steroids at 12 months
Study: 9525435
Drug: Cidofovir 3
Normalized name: cidofovir 375 MG in 5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cidofovir 3 mg/kg once every other week
Study: 9525435
Drug: Cidofovir therapy
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cidofovir therapy
Study: 7893034
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg/kg) and vecuronium (0.15 mg/kg)
Study: 17298428
Drug: Tacrolimus 0.03%
Normalized name: TACROLIMUS 0.03% OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 0.03% ointment
Study: 31668003
Drug: Tacrolimus 0.03%
Normalized name: TACROLIMUS 0.03% OINT,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 0.03% ointment and microdermabrasion
Study: 22776634
Drug: Lurasidone 40
Normalized name: lurasidone 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 40 mg/d
Study: 22776634
Drug: Lurasidone 80
Normalized name: lurasidone 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 80 mg/d
Study: 30172595
Drug: Risperidone 4
Normalized name: risperidone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 4 mg/d
Study: 16715687
Drug: Short duration
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short duration regimen (60 mg per day tapered over 12 weeks)
Study: 16715687
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose regimen (60 mg per day tapered over 20 weeks)
Study: 11547070
Drug: Intrarectal instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal instillation of 2% lidocaine gel
Study: 9337437
Drug: Sequential intravenous‐to‐oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential intravenous‐to‐oral ofloxacin
Study: 9337437
Drug: Standard intravenous‐to‐oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous‐to‐oral switch therapy
Study: 9337437
Drug: Standard switch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard switch therapy
Study: 7835811
Drug: Cisplatin (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (adjuvant treatment)
Study: 7835811
Drug: 32P (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32P (adjuvant treatment)
Study: 7835811
Drug: Observation (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (adjuvant treatment)
Study: 3680564
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) dextromethorphan (DM) suspension 60 mg bid
Study: 3680564
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) DM solution 30 mg qid
Study: 25910532
Drug: remifentanil (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil (0.4 μg/kg per minute) and saline solution
Study: 22981952
Drug: Placebo, n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, n = 40, orally, in 5 drops, 1 time daily, for 21 days
Study: 20350523
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg at 12 h pre-PCI and 40 mg at 2 h pre-PCI, followed by atorvastatin 40 mg/day for 30 days post-PCI
Study: 20350523
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care including atorvastatin 40 mg/day for 30 days post-PCI
Study: 12860331
Drug: Ureaplasma urealyticum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ureaplasma urealyticum positive cultures (>10(5) cfu/ml) in endometritis patients (39% of 67 patients)
Study: 8181026
Drug: Nonglycosidic inotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonglycosidic inotropic drugs (vesnarinone and ibopamine)
Study: 8181026
Drug: Adrenergic agents
Normalized name: ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenergic agents and phosphodiesterase inhibitors
Study: 28666080
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) at a standard dose (200 mg every 2 weeks plus optimized methotrexate)
Study: 23328304
Drug: 4-galactosylxylose (gaxilose)
Normalized name: Gaxilose
DrugBank: Gaxilose (DB12767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-galactosylxylose (gaxilose) at doses of 0.45 g for urine tests and 2.7 g for blood tests
Study: 20549321
Drug: Thymosin alpha
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha 1 (TA1) 3.2 mg twice per day for 7 days
Study: 20549321
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy for SAP
Study: 17448266
Drug: Estrogen, selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen, selective estrogen receptor modulators (SERMs), and bisphosphonates (when given in combination with calcium and vitamin D)
Study: 10776742
Drug: Regular-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular-dose aprotinin
Study: 11795347
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (HRT)
Study: 9459084
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg i.m. leuprolide acetate (LA) every 4 weeks for 24 weeks
Study: 8043891
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 mg/day)
Study: 31156221
Drug: neuroleptic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: neuroleptic therapy in combination with intravenous infusions of remaxol (400.0 ml)
Study: 27956428
Drug: MEDI8897 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI8897 (300 mg i.m.)
Study: 27956428
Drug: MEDI8897 (i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI8897 (i.m. dosing)
Study: 26115690
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser plus routine physical therapy program (RPTP)
Study: 23557930
Drug: GSK1322322 (500-1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1322322 (500-1500 mg)
Study: 23557930
Drug: GSK1322322 (1000-1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1322322 (1000-1500 mg)
Study: 21747084
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 5) and pemetrexed (500 mg/m(2)) every 21 days for four cycles and thoracic radiation therapy (TRT) (70 Gy) with cetuximab administered concurrent only with TRT
Study: 15248052
Drug: New Carisolv
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Carisolv gel (higher concentration of sodium hypochlorite)
Study: 8235809
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy with advice for daily life by a physiotherapist
Study: 8235809
Drug: Placebo ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ultrasound therapy by a physiotherapist
Study: 3321756
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Ibuprofen q.i.d. as pellets
Study: 3321756
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Ibuprofen b.i.d. as dragees
Study: 31940011
Drug: Family-Focused Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-Focused Therapy (FFT) - 12 sessions in 4 months of psychoeducation, communication training, and problem-solving skills training
Study: 26797192
Drug: Low-level light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level light therapy using the Color DNA-WSF device
Study: 26797192
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with a dummy device
Study: 18583261
Drug: rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (4 mg/day)
Study: 17602039
Drug: Rocuronium 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.45 mg.kg(‐1) iv (1.5 x ED(95))
Study: 17602039
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg.kg(‐1) iv (2.0 x ED(95))
Study: 27265451
Drug: PRP-CRM197 vaccine
Normalized name: Globo H-CRM197 vaccine
DrugBank: OBI-833 (DB19270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-CRM197 vaccine
Study: 8337029
Drug: PRP-T vaccine
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-T vaccine
Study: 27265451
Drug: PRP-CRM197 vaccine
Normalized name: Globo H-CRM197 vaccine
DrugBank: OBI-833 (DB19270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-CRM197 vaccine with DTaP
Study: 27265451
Drug: PRP-T vaccine
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-T vaccine with DTaP
Study: 19841897
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion (5-15 microg/min)
Study: 17478939
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg intravenously twice daily
Study: 17478939
Drug: Ranitidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine treatment group
Study: 16983112
Drug: Exatecan plus
Normalized name: Exatecan
DrugBank: Exatecan (DB12185)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exatecan plus gemcitabine (exatecan 2.0 mg/m2 and gemcitabine 1,000 mg/m2 on days 1 and 8, every 3 weeks)
Study: 8568135
Drug: Local nasal
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local nasal immunotherapy with allergen in powder form
Study: 6889140
Drug: Elixophyllin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elixophyllin 400 mg capsule
Study: 6889140
Drug: Elixophyllin 373
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elixophyllin 373 mg elixir
Study: 6889140
Drug: Theolair 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theolair 375 mg tablet
Study: 30971235
Drug: Cyclophosphamide (CYC)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CYC) added to high-dose corticosteroids
Study: 30971235
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to high-dose corticosteroids
Study: 26160253
Drug: Aggressive early
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aggressive early feeding guidelines (enteral and parenteral nutrition)
Study: 11131781
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (400 microg)
Study: 17579200
Drug: VA2914 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: VA2914 (5 mg/d)
Study: 10575335
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia without volatile anesthetics
Study: 7568654
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy plus consultation
Study: 2291838
Drug: Metformin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1.0 g/day
Study: 27930939
Drug: Guided Parent-delivered
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Parent-delivered Cognitive Behaviour Therapy (GPD-CBT) for 2.6 hours
Study: 27930939
Drug: Guided Parent-delivered
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Parent-delivered Cognitive Behaviour Therapy (GPD-CBT) for 5.3 hours
Study: 27930939
Drug: Guided Parent-delivered
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Parent-delivered Cognitive Behaviour Therapy (GPD-CBT)
Study: 21055588
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups pooled
Study: 23964994
Drug: benfotiamine 900
Normalized name: BENFOTIAMINE
DrugBank: Benfotiamine (DB11748)
Approvals — FDA: no, EMA: no, PMDA: no
Description: benfotiamine 900 mg/day for 6 weeks
Study: 18310262
Drug: Helicobacter pylori
Normalized name: HELICOBACTER PYLORI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helicobacter pylori test and treat (H pylori 13C urea breath test plus one week of eradication treatment if positive)
Study: 11039005
Drug: Auricular-plaster therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular-plaster therapy plus acupuncture at Zusanli (ST 36)
Study: 8721275
Drug: Total percentages
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total percentages of metabolites recovered in urine after i.v. administration
Study: 8721275
Drug: Total percentages
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total percentages of metabolites recovered in urine after i.c. administration without a tourniquet
Study: 8721275
Drug: Total percentages
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total percentages of metabolites recovered in urine after i.c. administration with a tourniquet
Study: 1443353
Drug: Cefotaxime (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1-g single dose 30 minutes before surgery)
Study: 1443353
Drug: Cefoxitin (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (1-g dose 30 minutes before surgery and 1 g every 6 hours for 24 hours, total dose 4 g)
Study: 1443353
Drug: Cefazolin (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1-g dose 30 minutes before surgery, followed by 1 g every 8 hours for 48 hours, total dose 6 g)
Study: 3904673
Drug: Polyester antimicrobial
Normalized name: polyester-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyester antimicrobial incise drape (loban 2 Antimicrobial Film) with one-minute skin preparation using 70% alcohol or 2% iodine in 90% alcohol
Study: 3904673
Drug: Standard ten-minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ten-minute skin preparation with Betadine
Study: 29244026
Drug: Pimodivir 1,200/600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimodivir 1,200/600 mg
Study: 22486142
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of ketamine
Study: 20360429
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic drug (ND)
Study: 11302304
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg sodium hyaluronate
Study: 9288374
Drug: Oxygen via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen via a facemask at 4 l/min
Study: 8323999
Drug: Phosphatidylserine (BC-PS)
Normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylserine (BC-PS) 300 mg/day for 6 months